No peer-reviewed clinical trials or human studies on Cartalax peptide (AED/T-31) have been published in major scientific journals. All available evidence comes from preclinical research, primarily in cell cultures and animal models, with most work originating from Russian research groups associated with Vladimir Khavinson.
The preclinical research is linked to BioLongevity Labs...
[Imported image pending local asset: attachments-1770270560294-webp.15550]
the guys who make and sell it.
I do see other studies like
here: but judging by the title, Peptides Regulate Expression of Signaling Molecules in Kidney Cell Cultures during In Vitro Aging , you should be using it for healthier kidneys.
Let's rename it ... kidnalax !
oh , gets even better, from the Biolab place i just mentioned:
[Imported image pending local asset: attachments-1770270981379-webp.15551]
Look You can increase NF-kB. Who else wants to upregulate the inflammasome 1.6 - 5.6 fold!?
in all honesty, the upregulation of FOXO1 and TERT maybe a good thing, but there's too much of a conflict of interest.
[Imported image pending local asset: attachments-1770274642631-webp.15554]
oops FOXO1 is downregulated and NFkB upregulated by KED, aka Vesugen . well I know to stay away from that one. (
linked paper)
Ultimately, I'm too ignorant regarding this AED bioregulator to really comment (who isn't!), but there's no chance I would inject this into my octogenarian mother.